Obesity ETF (SLIM)
| Bid | - |
| Market Cap | 11.34M |
| AUM | 11.63M |
| NAV | 34.12 |
| EPS (ttm) | 0.00 |
| PE Ratio (ttm) | n/a |
| Shares Out | 340.96K |
| Inception Date | Jun 8, 2016 |
| Ask | - |
| Volume | 6,313 |
| Open | 35.36 |
| Previous Close | 36.16 |
| Day's Range | 33.00 - 36.62 |
| 52-Week Range | 33.00 - 43.40 |
| Holdings | 0 |
| Expense Ratio | 0.35% |
About SLIM
The investment seeks investment results that correspond generally to the performance, before fees and expenses, of an index which is designed to track the performance of companies globally that are positioned to profit from servicing the obese, including biotechnology, pharmaceutical, health care and medical device companies whose business is focused on obesity and obesity related disease and companies focused on weight loss programs, weight loss supplements, or plus sized apparel. The fund invests at least 80% of its net assets in the stocks that comprise the Solactive Obesity Index. It is non-diversified.
Top Sectors
| Sector | Weight % |
|---|---|
| Healthcare | 91.86% |
| Consumer Defensive | 4.25% |
| Consumer Cyclical | 3.89% |
Dividends Dividend Yield 0.59%
| Ex-Dividend | Amount | Payment Date |
|---|---|---|
| Dec 19, 2019 | $0.0054 | Dec 26, 2019 |
| Sep 30, 2019 | $0.0520 | Oct 4, 2019 |
| Jun 28, 2019 | $0.0710 | Jul 5, 2019 |
| Mar 29, 2019 | $0.0917 | Apr 4, 2019 |
| Dec 20, 2018 | $0.0068 | Dec 27, 2018 |
1 week ago · proactiveinvestors.co.uk
Mounjaro, Ozempic: Obesity market shifting to portfolio play as GLP-1 innovation peaks, says leading bankGoldman Sachs analysts say the obesity drug market is entering a new phase where breadth of treatment options, rather than reliance on a single blockbuster, will determine long-term winners. Wrapping ...
2 weeks ago · investopedia.com
Novo Nordisk Stock Rises on Trial Results for Cagrilintide Obesity TreatmentU.S.-listed shares of Novo Nordisk (NVO) gained after the drugmaker reported positive results from a late-stage study of a weight-loss drug that works differently than traditional GLP-1 inhibitors.
